F-18 FES PET shows efficacy in early-stage breast cancer detection

09/4/2013 | MolecularImaging.net

A study in the Journal of Nuclear Medicine suggests that using F-18 FES PET to assess estrogen receptor expression could aid in the detection of early-stage breast cancer, but disease severity and tumor size may pose limitations. In the 48-patient perioperative study, F-18 FES PET showed 85% overall sensitivity in spotting early-stage breast cancer, but it did not identify small volume tumors, researchers said. Researchers also found that F-18 FES PET uptake correlated with immunohistochemistry ER expression and the main tumor's size.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC